MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Perrigo Co PLC

Geschlossen

BrancheGesundheitswesen

26.87 -3.69

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

26.81

Max

27.9

Schlüsselkennzahlen

By Trading Economics

Einkommen

-24M

-45M

Verkäufe

51M

1.1B

KGV

Branchendurchschnitt

2,570

63.778

EPS

0.93

Dividendenrendite

4.14

Gewinnspanne

-3.909

Angestellte

8,379

EBITDA

35M

114M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+19.42% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.14%

2.39%

Nächstes Ergebnis

6. Mai 2025

Nächste Dividendenausschüttung

17. Juni 2025

Nächstes Ex-Dividendendatum

29. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

459M

3.8B

Vorheriger Eröffnungskurs

30.56

Vorheriger Schlusskurs

26.87

Nachrichtenstimmung

By Acuity

35%

65%

122 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Perrigo Co PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Feb. 2025, 17:42 UTC

Wichtige Markttreiber

Perrigo Shares Jump on FDA's Move to Reclassify Wisconsin Infant-Formula Plant

27. Feb. 2025, 23:52 UTC

Ergebnisse

Perrigo Gets Facility Reclassification From FDA as 4Q Profit, Revenue Fall

Peer-Vergleich

Kursveränderung

Perrigo Co PLC Prognose

Kursziel

By TipRanks

19.42% Vorteil

12-Monats-Prognose

Durchschnitt 33.33 USD  19.42%

Hoch 42 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Perrigo Co PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

1

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

27.74 / 28.055Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

122 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Perrigo Co PLC

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.